Compare
Cytokinetics Inc vs Standard Biotools Inc. vs ARS Pharmaceuticals, Inc. vs Nurix Therapeutics, Inc.
| Latest fiscal year | Cytokinetics Inc CYTK | Standard Biotools Inc. LAB | ARS Pharmaceuticals, Inc. SPRY | Nurix Therapeutics, Inc. NRIX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-11-30 |
| Revenue | $88.04M | $85.33M | $84.28M | $83.98M |
| Revenue growth (YoY) | +376.6% | -6.2% | -5.5% | +54.0% |
| Gross margin | n/a | 49.9% | n/a | n/a |
| Operating margin | -695.4% | -129.2% | -212.9% | -340.2% |
| Net margin | -891.6% | -87.8% | -203.3% | -314.9% |
| Net income | -$784.96M | -$74.90M | -$171.30M | -$264.46M |
| EPS (Diluted) | -$6.54 | -$0.20 | -$1.74 | -$3.05 |
| Operating cash flow | -$510.01M | -$74.34M | -$170.87M | -$249.47M |
| Free cash flow | -$534.82M | -$82.65M | -$171.21M | -$263.47M |
| Cash & equivalents | $122.52M | $120.86M | $41.32M | $246.96M |
| Total assets | $1.42B | $567.75M | $327.65M | $688.13M |
| Total liabilities | $2.08B | $143.46M | $213.39M | $149.39M |
| Shareholders' equity | -$659.62M | $424.29M | $114.26M | $538.75M |
| Return on year-end equity | n/a | -17.7% | -149.9% | -49.1% |
| Shares outstanding | 122.94M | 386.38M | 99.29M | 101.81M |
Revenue, most recent five fiscal years
| Fiscal year | Cytokinetics Inc | Standard Biotools Inc. | ARS Pharmaceuticals, Inc. | Nurix Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $88.04M Ended 2025-12-31 | $85.33M Ended 2025-12-31 | $84.28M Ended 2025-12-31 | $83.98M Ended 2025-11-30 |
| 1 year earlier | $18.47M Ended 2024-12-31 | $91.01M Ended 2024-12-31 | $89.15M Ended 2024-12-31 | $54.55M Ended 2024-11-30 |
| 2 years earlier | $7.53M Ended 2023-12-31 | $106.34M Ended 2023-12-31 | $30.0K Ended 2023-12-31 | $76.99M Ended 2023-11-30 |
| 3 years earlier | $94.59M Ended 2022-12-31 | $97.95M Ended 2022-12-31 | $1.32M Ended 2022-12-31 | $38.63M Ended 2022-11-30 |
| 4 years earlier | $70.43M Ended 2021-12-31 | $130.58M Ended 2021-12-31 | $5.51M Ended 2021-12-31 | $29.75M Ended 2021-11-30 |